Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05438420 |
| Title | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Qurient Co., Ltd. |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University of Southern California | RECRUITING | Los Angeles | California | 90033 | United States | Details |
| Norton Cancer Institute | RECRUITING | Louisville | Kentucky | 40202 | United States | Details |
| CHA Bundang Medical Center | RECRUITING | Seongnam-si | Korea, Republic of | Details | ||
| Asan Medical Center | NOT_YET_RECRUITING | Seoul | Korea, Republic of | Details | ||
| Samsung Medical Center | RECRUITING | Seoul | Korea, Republic of | Details | ||
| Seoul National University Hospital | RECRUITING | Seoul | Korea, Republic of | Details | ||
| Severance Hospital | RECRUITING | Seoul | Korea, Republic of | Details |